Core Viewpoint - The company, Haixiang Pharmaceutical, expects a net loss attributable to shareholders of between -135 million and -90 million yuan for 2025, indicating a narrowing of losses compared to previous periods [1] Group 1: Financial Performance - The company is maintaining stable production and operations while enhancing management efficiency and risk resilience, leading to a reduction in the loss margin for 2025 [1] - The pharmaceutical segment experienced mixed price changes for key products, with rising raw material costs impacting overall revenue slightly and continuing pressure on gross margins [1] - The dye segment saw a recovery in profitability, with core product prices increasing significantly [1] Group 2: Market Conditions - The introduction of new products, such as peptides, is growing rapidly but remains in the cultivation stage, contributing to the overall revenue decline in the pharmaceutical segment [1] - The ongoing depreciation of the US dollar against the Chinese yuan has had a significant negative impact on the net profit attributable to shareholders for the current period [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性 陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | -13,500 | ～ | -9,000 | -33,026.72 | | 扣除非经常性损 益后的净利润 | -14,200 | ～ | -9,500 | -340,277.1 | | 基本每股收益 （元/股） | -0.08 | ～ | -0.06 | -0.21 | 二、与会计师事务所沟通情况 证券代码：002099 证券简称：海翔药业 公告编号：2026-005 浙江海翔药业股份有限公司 2025 年度业绩预告 三、业绩变动原因说明 1、报告期内，公司稳健开展生产经营，同时持续深化精细管理，提升运营效率与抗 风险能力，2025 年度亏损幅度有所收窄。医药板块主要产品价格涨跌 ...

Core Viewpoint - Haisheng Pharmaceutical (002099.SZ) has received approval from the National Medical Products Administration for the marketing application of Diquafosol Sodium, a P2Y2 receptor agonist used in eye drop formulation for the treatment of dry eye disease [1] Group 1 - Diquafosol Sodium acts on the P2Y2 receptors located on the conjunctival epithelium and goblet cell membranes [1] - The mechanism of Diquafosol Sodium involves upregulating intracellular calcium ion concentration, which promotes the secretion of water and mucin, thereby improving symptoms of dry eye [1]

Core Viewpoint - The company has received approval from the National Medical Products Administration for the marketing application of Diquafosol Sodium, a P2Y2 receptor agonist used in eye drops for the treatment of dry eye disease [1] Group 1: Company Information - The approved product, Diquafosol Sodium, is specifically formulated as an eye drop solution [1] - The company anticipates that the sales revenue for Diquafosol Sodium eye drops in urban public hospitals in China will reach RMB 131 million in 2024 [1] Group 2: Industry Context - Diquafosol Sodium is positioned within the therapeutic area of dry eye disease, which is a significant market in ophthalmology [1]

Core Viewpoint - The approval of the sodium diquafosol raw material drug by the National Medical Products Administration enhances the company's product pipeline and competitiveness, although it will not have a significant short-term impact on performance due to pending GMP inspections and various uncertainties regarding production and sales timing [1] Group 1 - The company has received the approval notice for the sodium diquafosol raw material drug, which is packaged in 5kg barrels and meets drug registration requirements [1] - Sodium diquafosol is a P2Y2 receptor agonist, and its eye drops are used for the treatment of dry eye syndrome, with projected sales of 130.89 million yuan in public hospitals in Chinese cities in 2024 [1] - The approval will enrich the company's product pipeline and enhance its competitiveness in the market [1] Group 2 - The company still needs to pass GMP inspections, which introduces uncertainty regarding the short-term impact on performance [1] - The timing and conditions of production and sales are influenced by multiple factors, leading to further uncertainties [1]

一、药品注册批准情况 化学原料药名称：地夸磷索钠 生产企业：浙江海翔药业股份有限公司，浙江省台州市椒江区外沙支路 100 号 包装规格：5kg/桶 证券代码：002099 证券简称：海翔药业 公告编号：2026-004 浙江海翔药业股份有限公司 关于获得地夸磷索钠化学原料药上市申请批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，浙江海翔药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局核准签发的地夸磷索钠《化学原料药上市申请批准通知书》。现就相关情 况公告如下： 地夸磷索钠是一种 P2Y2 受体激动剂，其滴眼液制剂用于干眼症的治疗。地 夸磷索钠作用于结膜上皮及杯状细胞膜上的 P2Y2 受体，通过上调细胞内的钙离 子浓度，促进水分及黏蛋白的分泌，进而改善干眼病症状。 据米内网数据显示，地夸磷索钠滴眼液 2024 年在中国城市公立医院的销售 额为人民币 13,089 万元。 三、对公司的影响 公司地夸磷索钠原料药获得上市申请批准通知书，表明该原料药已符合国家 相关药品审评技术标准，将丰富公司特色原料药产品管线，提升公司综合竞争力。 ...

Group 1 - The core point of the article is that Haixiang Pharmaceutical reported a total of 30,934 shareholders as of January 20, 2026 [2]

Core Viewpoint - The company, Zhejiang Haixiang Pharmaceutical Co., Ltd., is actively involved in investment activities and has recently made significant moves regarding its employee stock ownership plan and investments in other firms, which may impact investor confidence and stock performance. Group 1: Stock Performance and Market Activity - As of January 19, 2026, Haixiang Pharmaceutical's stock closed at 6.54 yuan, reflecting a 0.31% increase, with a turnover rate of 1.22% and a trading volume of 196,700 shares, amounting to a transaction value of 128 million yuan [1] - On January 19, the net inflow of funds from major investors was 7.80 million yuan, while speculative funds saw a net inflow of 9.57 million yuan, contrasted by a net outflow of 17.37 million yuan from retail investors [2][4] Group 2: Corporate Announcements and Investments - The company announced its participation in establishing the Hangzhou Fuhong Equity Investment Partnership with an investment of 100 million yuan, specifically targeting non-listed shares of Fuhong Hanlin [3] - As of January 19, 2026, the company received notification that Fuhong Hanlin has been registered with the China Securities Regulatory Commission, and some of its shareholders' domestic unlisted shares will be converted to H-shares for listing on the Hong Kong Stock Exchange, pending further regulatory procedures [3][4]

证券代码：002099 证券简称：海翔药业 公告编号：2026-003 浙江海翔药业股份有限公司 关于参投合伙企业投资复宏汉霖的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特此公告。 浙江海翔药业股份有限公司 董 事 会 浙江海翔药业股份有限公司（以下简称"公司"）第六届董事会第十二次会 议审议《关于参与设立合伙企业投资复宏汉霖的议案》，同意公司出资 1 亿元人 民币，参与发起设立台州富宏股权合伙企业（有限合伙）【现已更名："杭州复 宏股权投资合伙企业（有限合伙）"，以下简称"合伙企业"】。该合伙企业为 专项基金，专项投资于上海复宏汉霖生物技术股份有限公司（证券简称："复宏 汉霖"，证券代码：02696）的非上市股份。具体内容详见巨潮资讯网及 2021 年 6 月 5 日在《证券时报》《中国证券报》《上海证券报》《证券日报》刊登的 《关于参与设立合伙企业投资复宏汉霖的公告》（公告编号：2021-023）。 二、本次投资进展情况 2026 年 1 月 19 日，公司收到合伙企业出具的《2026 年 1 月项目运作临时管 理报告》，告知复宏汉霖于近日 ...

Commercial Aerospace - Lichong Group supplies high-end aluminum-based functional intermediate alloys for the commercial aerospace sector [1] Humanoid Robots - Shiyun Circuit has secured a new generation humanoid robot project [1] AI Applications - Longkun Technology's AI biopharmaceutical project is currently in the pre-clinical stage [1] - Bona Film Group has officially launched AI tools "Bole One-Click AI Short Drama" and "Bole Round Table" [1] Other Developments - CATL is advancing high energy density battery technologies, including condensed and solid-state batteries, for aviation applications [1] - Haixiang Pharmaceutical's invested Yuxin Fund holds a 1.352% stake in Tianbing Technology [1] - Zhejiang Fu Holdings reports that rising commodity prices have a positive impact on the company's performance [1] - Meiansen has no collaboration with the European Dorgerberg Steel Plant [1] - Zhite New Materials has no business or revenue related to AI applications, quantum technology, or artificial intelligence [1] - Woge Optoelectronics has completed small batch sample delivery of 1.6T optical module glass-based substrates [1]